Stay on the Pulse of Federal and State Reporting Requirements, Policy Initiatives and Strategic Best Practices for Compliance
Join CBI’s 6th Edition Drug Pricing Transparency Congress, to gather with industry stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Recent federal and state rulings continue to create lingering questions around legislation and compliance complexities that impact the market in real-time. This uncertainty, in addition to the recent HHS proposal to eliminate rebates, the final ruling on DTC advertisements regarding list prices and the Senate Finance hearing with Pharma CEOs, emphasizes a heightened focus on drug pricing transparency in the United States. Assess the legislative landscape entering into 2020, share best practices for implementation and dive into new state transparency laws to date.